<?xml version='1.0' encoding='utf-8'?>
<document id="24806030"><sentence text="Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects."><entity charOffset="67-75" id="DDI-PubMed.24806030.s1.e0" text="acarbose" /><entity charOffset="80-89" id="DDI-PubMed.24806030.s1.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24806030.s1.e0" e2="DDI-PubMed.24806030.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s1.e0" e2="DDI-PubMed.24806030.s1.e1" /></sentence><sentence text="Both metformin and acarbose are recommended monotherapy and add-on therapy in type 2 diabetes mellitus (T2DM)"><entity charOffset="5-14" id="DDI-PubMed.24806030.s2.e0" text="metformin" /><entity charOffset="19-27" id="DDI-PubMed.24806030.s2.e1" text="acarbose" /><pair ddi="false" e1="DDI-PubMed.24806030.s2.e0" e2="DDI-PubMed.24806030.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s2.e0" e2="DDI-PubMed.24806030.s2.e1" /></sentence><sentence text=" A fixed-dose combination (FDC) of acarbose and metformin has been developed to reduce pill burden and potentially improve compliance"><entity charOffset="35-43" id="DDI-PubMed.24806030.s3.e0" text="acarbose" /><entity charOffset="48-57" id="DDI-PubMed.24806030.s3.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24806030.s3.e0" e2="DDI-PubMed.24806030.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s3.e0" e2="DDI-PubMed.24806030.s3.e1" /></sentence><sentence text=" The current study investigated the bioequivalence of the acarbose/metformin FDC compared with the individual agents administered simultaneously (loose combination)"><entity charOffset="58-66" id="DDI-PubMed.24806030.s4.e0" text="acarbose" /><entity charOffset="67-80" id="DDI-PubMed.24806030.s4.e1" text="metformin FDC" /><pair ddi="false" e1="DDI-PubMed.24806030.s4.e0" e2="DDI-PubMed.24806030.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s4.e0" e2="DDI-PubMed.24806030.s4.e1" /></sentence><sentence text=" Secondary endpoints were the safety and tolerability of the FDC and the potential for drug-drug interactions between acarbose and metformin"><entity charOffset="118-126" id="DDI-PubMed.24806030.s5.e0" text="acarbose" /><entity charOffset="131-140" id="DDI-PubMed.24806030.s5.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24806030.s5.e0" e2="DDI-PubMed.24806030.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s5.e0" e2="DDI-PubMed.24806030.s5.e1" /></sentence><sentence text="" /><sentence text="A single-centre, randomized, open-label, four-period crossover study was conducted in healthy male Korean subjects aged 18-45 years" /><sentence text=" Following one-period balanced Williams design, participants were randomized to receive four single oral treatments on different study days separated by ≥7 days' washout" /><sentence text=" Treatments were as follows: (i) acarbose/metformin 50/500 mg FDC (test); (ii) acarbose 50 mg and metformin 500 mg as loose combination (reference); (iii) acarbose 50 mg; and (iv) metformin 500 mg"><entity charOffset="33-41" id="DDI-PubMed.24806030.s9.e0" text="acarbose" /><entity charOffset="42-51" id="DDI-PubMed.24806030.s9.e1" text="metformin" /><entity charOffset="62-65" id="DDI-PubMed.24806030.s9.e2" text="FDC" /><entity charOffset="79-87" id="DDI-PubMed.24806030.s9.e3" text="acarbose" /><entity charOffset="98-107" id="DDI-PubMed.24806030.s9.e4" text="metformin" /><entity charOffset="155-163" id="DDI-PubMed.24806030.s9.e5" text="acarbose" /><entity charOffset="180-189" id="DDI-PubMed.24806030.s9.e6" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e0" e2="DDI-PubMed.24806030.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e0" e2="DDI-PubMed.24806030.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e0" e2="DDI-PubMed.24806030.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e0" e2="DDI-PubMed.24806030.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e0" e2="DDI-PubMed.24806030.s9.e4" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e0" e2="DDI-PubMed.24806030.s9.e5" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e0" e2="DDI-PubMed.24806030.s9.e6" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e1" e2="DDI-PubMed.24806030.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e1" e2="DDI-PubMed.24806030.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e1" e2="DDI-PubMed.24806030.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e1" e2="DDI-PubMed.24806030.s9.e4" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e1" e2="DDI-PubMed.24806030.s9.e5" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e1" e2="DDI-PubMed.24806030.s9.e6" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e2" e2="DDI-PubMed.24806030.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e2" e2="DDI-PubMed.24806030.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e2" e2="DDI-PubMed.24806030.s9.e4" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e2" e2="DDI-PubMed.24806030.s9.e5" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e2" e2="DDI-PubMed.24806030.s9.e6" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e3" e2="DDI-PubMed.24806030.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e3" e2="DDI-PubMed.24806030.s9.e4" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e3" e2="DDI-PubMed.24806030.s9.e5" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e3" e2="DDI-PubMed.24806030.s9.e6" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e4" e2="DDI-PubMed.24806030.s9.e4" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e4" e2="DDI-PubMed.24806030.s9.e5" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e4" e2="DDI-PubMed.24806030.s9.e6" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e5" e2="DDI-PubMed.24806030.s9.e5" /><pair ddi="false" e1="DDI-PubMed.24806030.s9.e5" e2="DDI-PubMed.24806030.s9.e6" /></sentence><sentence text=" Serial blood samples were taken for glucose and insulin levels for 4 h after a sucrose load on the day before and day of study drug administration"><entity charOffset="37-44" id="DDI-PubMed.24806030.s10.e0" text="glucose" /><entity charOffset="80-87" id="DDI-PubMed.24806030.s10.e1" text="sucrose" /><pair ddi="false" e1="DDI-PubMed.24806030.s10.e0" e2="DDI-PubMed.24806030.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s10.e0" e2="DDI-PubMed.24806030.s10.e1" /></sentence><sentence text=" Additionally, serial blood samples were taken for analysis of metformin levels for 24 h after each drug containing metformin"><entity charOffset="63-72" id="DDI-PubMed.24806030.s11.e0" text="metformin" /><entity charOffset="116-125" id="DDI-PubMed.24806030.s11.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24806030.s11.e0" e2="DDI-PubMed.24806030.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s11.e0" e2="DDI-PubMed.24806030.s11.e1" /></sentence><sentence text=" The area under the curve for 4 h post-test (AUC0-4 h ) and the maximal serum concentration (Cmax ) of plasma glucose and serum insulin were primary pharmacodynamic (PD) parameters, and Cmax , AUC0-last and AUC for metformin levels were primary pharmacokinetic (PK) parameters"><entity charOffset="110-117" id="DDI-PubMed.24806030.s12.e0" text="glucose" /><entity charOffset="215-224" id="DDI-PubMed.24806030.s12.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24806030.s12.e0" e2="DDI-PubMed.24806030.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s12.e0" e2="DDI-PubMed.24806030.s12.e1" /></sentence><sentence text=" The bioequivalence of the FDC to the loose combination was considered established if the 90% confidence intervals (CIs) of the baseline-adjusted PD parameter ratios (test vs"><entity charOffset="27-35" id="DDI-PubMed.24806030.s13.e0" text="FDC" /></sentence><sentence text=" reference) for plasma glucose and the PK parameter ratios for metformin fell completely within current acceptance limits (0·8-1·25)"><entity charOffset="23-30" id="DDI-PubMed.24806030.s14.e0" text="glucose" /><entity charOffset="63-72" id="DDI-PubMed.24806030.s14.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24806030.s14.e0" e2="DDI-PubMed.24806030.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s14.e0" e2="DDI-PubMed.24806030.s14.e1" /></sentence><sentence text="" /><sentence text="Thirty-three of 40 randomized subjects completed the study; five withdrew consent and two discontinued because of adverse events (AEs)" /><sentence text=" The 24-h plasma concentration-time curves of metformin and the 4-h plasma glucose-time curves after acarbose/metformin FDC (test) and acarbose + metformin loose combination (reference) were almost superimposable"><entity charOffset="46-55" id="DDI-PubMed.24806030.s17.e0" text="metformin" /><entity charOffset="75-82" id="DDI-PubMed.24806030.s17.e1" text="glucose" /><entity charOffset="101-109" id="DDI-PubMed.24806030.s17.e2" text="acarbose" /><entity charOffset="110-123" id="DDI-PubMed.24806030.s17.e3" text="metformin FDC" /><entity charOffset="120-132" id="DDI-PubMed.24806030.s17.e4" text="FDC" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e0" e2="DDI-PubMed.24806030.s17.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e0" e2="DDI-PubMed.24806030.s17.e1" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e0" e2="DDI-PubMed.24806030.s17.e2" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e0" e2="DDI-PubMed.24806030.s17.e3" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e0" e2="DDI-PubMed.24806030.s17.e4" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e1" e2="DDI-PubMed.24806030.s17.e1" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e1" e2="DDI-PubMed.24806030.s17.e2" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e1" e2="DDI-PubMed.24806030.s17.e3" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e1" e2="DDI-PubMed.24806030.s17.e4" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e2" e2="DDI-PubMed.24806030.s17.e2" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e2" e2="DDI-PubMed.24806030.s17.e3" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e2" e2="DDI-PubMed.24806030.s17.e4" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e3" e2="DDI-PubMed.24806030.s17.e3" /><pair ddi="false" e1="DDI-PubMed.24806030.s17.e3" e2="DDI-PubMed.24806030.s17.e4" /></sentence><sentence text=" The geometric least squares (LS) mean of the RatioAUC and RatioCmax for plasma glucose after the FDC vs"><entity charOffset="80-87" id="DDI-PubMed.24806030.s18.e0" text="glucose" /><entity charOffset="98-104" id="DDI-PubMed.24806030.s18.e1" text="FDC" /><pair ddi="false" e1="DDI-PubMed.24806030.s18.e0" e2="DDI-PubMed.24806030.s18.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s18.e0" e2="DDI-PubMed.24806030.s18.e1" /></sentence><sentence text=" loose combination, and the LS mean of the ratios in metformin AUC, AUC0-last and Cmax were close to unity, and the 90% CI of all these parameters fell within the predefined equivalence range of 0·8-1·25, confirming bioequivalence" /><sentence text=" The metformin AUC was reduced by 26% and Cmax by 34% after acarbose + metformin compared with metformin alone"><entity charOffset="5-14" id="DDI-PubMed.24806030.s20.e0" text="metformin" /><entity charOffset="60-80" id="DDI-PubMed.24806030.s20.e1" text="acarbose + metformin" /><entity charOffset="95-104" id="DDI-PubMed.24806030.s20.e2" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24806030.s20.e0" e2="DDI-PubMed.24806030.s20.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s20.e0" e2="DDI-PubMed.24806030.s20.e1" /><pair ddi="false" e1="DDI-PubMed.24806030.s20.e0" e2="DDI-PubMed.24806030.s20.e2" /><pair ddi="false" e1="DDI-PubMed.24806030.s20.e1" e2="DDI-PubMed.24806030.s20.e1" /><pair ddi="false" e1="DDI-PubMed.24806030.s20.e1" e2="DDI-PubMed.24806030.s20.e2" /></sentence><sentence text=" Eight subjects (20·0%) reported AEs, but all were mild, and most were gastrointestinal, as expected for these agents" /><sentence text=" The incidence of AEs was not higher with the combinations vs" /><sentence text=" monotherapy" /><sentence text="" /><sentence text="These data demonstrate that the acarbose/metformin FDC is bioequivalent to the loose combination of these agents"><entity charOffset="32-40" id="DDI-PubMed.24806030.s25.e0" text="acarbose" /><entity charOffset="41-54" id="DDI-PubMed.24806030.s25.e1" text="metformin FDC" /><entity charOffset="51-63" id="DDI-PubMed.24806030.s25.e2" text="FDC" /><pair ddi="false" e1="DDI-PubMed.24806030.s25.e0" e2="DDI-PubMed.24806030.s25.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s25.e0" e2="DDI-PubMed.24806030.s25.e1" /><pair ddi="false" e1="DDI-PubMed.24806030.s25.e0" e2="DDI-PubMed.24806030.s25.e2" /><pair ddi="false" e1="DDI-PubMed.24806030.s25.e1" e2="DDI-PubMed.24806030.s25.e1" /><pair ddi="false" e1="DDI-PubMed.24806030.s25.e1" e2="DDI-PubMed.24806030.s25.e2" /></sentence><sentence text=" Although acarbose slightly reduced the bioavailability of metformin, the accumulated evidence of the efficacy of this combination implies that this is clinically irrelevant"><entity charOffset="10-18" id="DDI-PubMed.24806030.s26.e0" text="acarbose" /><entity charOffset="59-68" id="DDI-PubMed.24806030.s26.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.24806030.s26.e0" e2="DDI-PubMed.24806030.s26.e0" /><pair ddi="false" e1="DDI-PubMed.24806030.s26.e0" e2="DDI-PubMed.24806030.s26.e1" /></sentence><sentence text=" The observed AE profile was consistent with the established knowledge on the safety of the two drugs" /><sentence text="" /></document>